Clavet

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Clavet

What is Clavet?

Clavet is a combination antibacterial medication used in veterinary medicine. It consists of two active pharmaceutical ingredients: amoxicillin and clavulanic acid. This combination is designed to treat various bacterial infections in animals, most commonly dogs and cats.

Composition and Mechanism

The effectiveness of Clavet is derived from the synergistic relationship between its two components:

  • Amoxicillin: A broad-spectrum antibiotic belonging to the penicillin family. It works by interfering with the synthesis of bacterial cell walls, leading to the eventual rupture and death of the bacteria.
  • Clavulanic Acid: While it has little antimicrobial activity on its own, clavulanic acid acts as a beta-lactamase inhibitor. Many bacteria produce enzymes called beta-lactamases that can deactivate amoxicillin. Clavulanic acid binds to these enzymes, preventing them from destroying the amoxicillin and allowing the antibiotic to remain effective against resistant strains.

Clinical Applications

Clavet is utilized to address infections caused by susceptible strains of organisms in several areas of the body, including:

  • Skin and Soft Tissue: Such as abscesses, cellulitis, and superficial or deep pyoderma.
  • Urinary Tract: Including infections of the bladder and kidneys.
  • Respiratory Tract: Management of upper and lower respiratory infections.
  • Periodontal Disease: Treatment of infections affecting the gums and supporting structures of the teeth.

Pharmaceutical Properties

By combining a penicillin-type antibiotic with a protector against bacterial resistance, Clavet extends the range of bacteria that can be successfully treated compared to using amoxicillin alone. It is effective against both Gram-positive and Gram-negative bacteria, including those that would otherwise be resistant to simple penicillin treatments.

Regulatory References

  1. Amoxicillin Clavulanate - StatPearls - NCBI Bookshelf

What side effects are possible with Clavet?

Possible Side Effects and Safety Information

The safety profile for this medicine (Amoxicillin and Clavulanate Potassium) is structured by government regulators to detail both common, expected reactions and serious, life-threatening risks.

Serious Adverse Reactions (Regulatory Warnings)

The official labeling includes prominent warnings about rare, but potentially fatal, hypersensitivity reactions (anaphylaxis) and severe skin reactions, such as Stevens-Johnson syndrome (SJS). Patients should also be aware of the risk of severe liver problems (hepatic dysfunction), including cholestatic jaundice, and a form of severe bowel inflammation called Clostridioides difficile-associated diarrhea (CDAD). These serious reactions require immediate medical attention.

Common and Uncommon Side Effects

Side effects are classified by their frequency, based on clinical trial data and post-marketing surveillance:

Frequency Side Effect Examples
Very Common (1/10) Diarrhea (especially in adults)
Common Nausea, Vomiting, Mucocutaneous candidiasis (thrush)
Uncommon Headache, Dizziness, Indigestion, Skin rash, Itching

Contraindications and Restrictions

The medicine is officially restricted for use in specific populations and situations:

  • Contraindicated (Not Allowed): Individuals with a history of serious allergic reactions to penicillin or cephalosporin antibiotics, or those with a prior history of liver problems or jaundice associated with this drug combination.
  • Cautions: Specific dose adjustments and close monitoring are necessary for patients with severe kidney impairment. Use in patients with infectious mononucleosis is generally advised against due to the high risk of rash.
  • Drug Interactions: Caution is advised when used alongside oral anticoagulants (e.g., warfarin) due to the risk of increased bleeding.

This information reflects the formal safety statements and limitations documented in official government regulatory documents.

Overdose and Emergency Response

Overdose and When to Seek Help

The information below is based strictly on the official overdose sections of government regulatory documents for Amoxicillin/Clavulanic Acid (Clavet). A specific antidote is not listed in regulatory labeling.

Feature Official Regulatory Statement
Documented Manifestations Primarily gastrointestinal symptoms (vomiting, diarrhea, abdominal pain, gastritis), drowsiness, hyperactivity, and rash may occur. Cloudy urine and a greatly decreased frequency or amount of urination are also documented presentations.
Severe Outcomes Convulsions or seizures are documented, particularly in patients with impaired renal function or after receiving high doses. The risk of Amoxicillin crystalluria is noted, which can lead to reversible oliguric renal failure (reduced urine output).
Emergency Actions If an overdose is suspected, the drug must be discontinued. Immediate medical attention is required to institute supportive care, especially given the risk of severe complications.

Required Supportive Measures:

  • Treatment must be symptomatic and supportive measures instituted as required.
  • Hemodialysis is described as an effective procedural step for removing both amoxicillin and clavulanic acid from the circulation.
  • It is advised to maintain adequate fluid intake and urinary output to reduce the possibility of Amoxicillin crystalluria.

The regulatory profile highlights that the major concern is not only the initial gastrointestinal symptoms but the potential for severe renal and neurological effects. The need for urgent medical help is derived from the requirement to manage these complications and to facilitate active drug removal via supportive procedures like hemodialysis.

Therapeutic Uses of Clavet

What Clavet Treats: Main Uses and Benefits

Clavet (Amoxicillin/Clavulanic Acid) is used for managing bacterial infections that present with heightened symptoms across several body systems, particularly in contexts involving bacteria with resistance characteristics. The combination is generally applied in settings where short-term symptomatic assistance for infections involving resistance is needed. Its use is relevant across therapeutic areas involving infections of the ears, lungs, sinus, skin, and urinary tract.

Core Therapeutic Domains and Symptom Relief

This medication may be part of symptomatic management across conditions presenting with acute episodes, including Community-Acquired Pneumonia (CAP), bronchitis, rhinosinusitis, otitis media, cellulitis, and complicated urinary tract infections (UTIs). Clavet is applied in clinical settings that involve acute or unstable symptom patterns. Its use is applied in addressing symptom clusters that may become intense or disruptive, such as fever, severe pain, and symptoms that create noticeable physiological strain.

Quick Fact: Support for Disruptive Symptoms

Quick Fact: Support for Description
Disruptive Symptoms Provides support that helps ease the overall symptom burden in conditions involving antibiotic resistance, assisting with maintaining comfort when symptoms interfere with routine activities.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Clavet?

The official regulatory profile for Clavet (Amoxicillin/Clavulanic Acid) defines strict population-based eligibility rules, primarily concerning hypersensitivity, organ function, and specific comorbidities.

Contraindicated Populations

The medicine is contraindicated in patients with a history of severe hypersensitivity to any penicillin or beta-lactam agent. It is also absolutely prohibited for those with a prior history of cholestatic jaundice or hepatic dysfunction specifically linked to this drug combination. Furthermore, use should be avoided in patients with Infectious Mononucleosis.

Restricted and Conditional Use

Organ Function: Patients with severe renal impairment (creatinine clearance less than 30 mL/min) require mandatory dosage adjustment, and certain high-dose or extended-release formulations are not recommended. Use in hepatic impairment requires caution and regular function monitoring.

Age and Life Stage: Use is established for adults and children. Specific tablet presentations are not recommended for children under 40 kg. Use during pregnancy is generally avoided unless necessary. Components are excreted in breast milk, requiring caution during lactation.

What should I know about interactions with other medicines?

Documented Interactions with Other Medicines

The official regulatory profile for Clavet (Amoxicillin/Clavulanic Acid) is defined by pharmacokinetic and pharmacodynamic interactions documented in government prescribing information.

Key Interaction Patterns

Interacting Agent Official Interaction Description
Probenecid Co-administration is officially noted as not recommended because the uric acid agent inhibits the renal tubular secretion of Amoxicillin. This transporter-mediated effect substantially increases and prolongs Amoxicillin plasma concentrations.
Methotrexate Co-administration is documented to increase and prolong the systemic exposure of Methotrexate. This is a pharmacokinetic effect caused by Amoxicillin competing for the same renal elimination pathway.
Oral Anticoagulants The combination with agents like Warfarin may lead to an abnormal prolongation of the Prothrombin Time and increase in the International Normalized Ratio (INR). This requires regulatory consideration and monitoring.
Allopurinol The concurrent use of Allopurinol is formally associated with an increased incidence of skin rash or hypersensitivity reactions, as noted in official labeling.
Combined Oral Contraceptives Official documents indicate that this medicine may reduce the efficacy of estrogen/progesterone-based oral contraceptives due likely to effects on intestinal flora.

Procedural and Timing Notes

Administration of this medicine is advised at the start of a meal to enhance the absorption of the Clavulanate Potassium component. In patients with severe renal impairment, the clearance of both active components is reduced, requiring regulatory-mandated management of exposure. High concentrations of Amoxicillin in urine may cause false-positive results when using non-enzymatic urine glucose tests (e.g., Clinitest) during diagnostic procedures.

Mechanism of Action

Clavet is an aminobisphosphonate that exhibits selective affinity for bone mineral surfaces, where it is internalized by active osteoclasts. Once inside the cell, the molecule primarily targets and inhibits the essential enzyme farnesyl pyrophosphate synthase (FPPS). FPPS is a critical component of the mevalonate pathway.

Inhibition of FPPS prevents the formation of farnesyl and geranylgeranyl pyrophosphate lipids. These lipids are necessary for the prenylation, a post-translational modification, of small signaling GTPase proteins, including Ras, Rho, and Rac. The non-prenylated GTPases cannot anchor to the plasma membrane, which disrupts the required intracellular signaling cascade for osteoclast function and cytoskeletal integrity.

This molecular cascade leads to the loss of the ruffled border structure, which is vital for bone resorption. Consequently, the osteoclast undergoes programmed cell death, or apoptosis. The systemic physiological consequence of this targeted cellular action is a net reduction in bone turnover due to decreased osteoclast activity and cell count.

Dosage and Administration Information

Instruction Map: How to use Clavet — Administration Guidelines

Clavet (Amoxicillin/Clavulanic Acid) is administered through two primary routes: the oral route (tablets, suspension) and the intravenous (IV) route (powder for injection). The specific method and dose are defined by standardized instructions.

Administration Scope

Entity Detail
Route of administration Oral and Intravenous (IV).
Dosing schedule (Adults) 875 mg/125 mg every mathbf12 hours or 500 mg/125 mg every mathbf8 hours (Amoxicillin component listed first).
Timing in relation to meals Oral forms must be taken at the start of a meal to enhance absorption and minimize potential gastrointestinal intolerance.
Age-group administration rules Pediatric: Dosing is weight-based and divided every mathbf8 or mathbf12 hours. Older Adults: No adjustment needed if renal function is normal.
Special procedural conditions The high-strength 875 mg tablet is prohibited for patients with moderate to severe renal impairment (CrCl < 30 mL/min). IV administration typically requires infusion over mathbf30 to mathbf40 minutes.
Course Duration Treatment should generally not be extended beyond mathbf14 days without a mandatory clinical re-evaluation.

Connection to the Overall Use Protocol

This structured protocol establishes the precise parameters for Clavet administration. It mandates a fixed interval (mathbf8 or mathbf12 hours) to ensure consistent drug exposure and requires administration at the start of a meal to meet absorption criteria. Furthermore, explicit rules govern dose reduction for renal impairment and define the mathbf14-day limit for standard use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Clavet

The research for the combination product Clavet (amoxicillin and clavulanic acid) includes numerous official studies, such as Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews referenced in materials submitted to and reviewed by regulatory bodies. These studies primarily focused on research examining the combination product's use context when infections involve bacteria capable of resisting certain antibiotics. Research provides context but not individual predictions, and study results reflect the specific conditions under which they were conducted.


Evidence for Use in Respiratory Tract and Ear Infections (CAP and AOM)

Clavet was studied for its role in conditions like Community-Acquired Pneumonia (CAP) and Acute Otitis Media (AOM) in both adults and children. These studies were often structured as short-term RCTs, exploring short-term symptom changes. Researchers examined outcomes related to systemic or functional imbalance, such as changes in fever and respiratory symptoms, and the status of targeted bacteria (microbiological status) over follow-up periods that usually extended to 30 days. Research describes the patterns observed in measured clinical outcomes across various treatment durations and contexts.


Evidence for Use in Sinus, Skin, and Urinary Tract Infections

Clavet was evaluated in research contexts involving conditions characterized by episodic or acute changes, specifically acute bacterial rhinosinusitis, complicated urinary tract infections (UTIs), and various skin and soft tissue infections. Studies monitored outcomes related to physical discomfort and microbiological status, with data showing patterns related to clearance of the targeted bacteria over defined time intervals. Follow-up durations were typically limited to a few weeks post-treatment, leaving longer-term patterns less characterized.


Understanding Research Gaps and Limitations

Scientific literature and regulatory assessments highlight several research limitations. Evidence quality varies across studies, and a key limitation is that comparative evidence is lacking for high-quality, direct, head-to-head trials against amoxicillin alone in all contexts. Research exploring the clinical necessity of the clavulanic acid component is sometimes supported by indirect evidence or extrapolation in certain populations. Furthermore, long-term outcomes regarding the durability of responses are not fully established by the existing core clinical trials.

Frequently Asked Questions (FAQ)

Common questions about Clavet (FAQ)

Q: What is Clavet actually used for?

A: Official regulatory documents describe Clavet as a prescription medicine used to treat specific types of bacterial infections. It is approved for addressing infections in areas like the ear, sinuses, lower respiratory tract (including pneumonia), skin, and urinary tract. This medicine is an antibacterial agent and is not effective against viral infections.

Q: Is Clavet a type of antibiotic?

A: Yes, Clavet is officially classified as an antibacterial drug. It is a combination medicine that pairs the penicillin-like agent amoxicillin with clavulanic acid, which is included to help overcome bacterial resistance mechanisms.

Q: Why do doctors prescribe Clavet instead of other options?

A: The drug is often prescribed because of its combination formula. One component fights bacteria, while the other component (clavulanic acid) is a 'beta-lactamase inhibitor' that protects the main ingredient from being broken down by certain bacterial enzymes. This combination helps it treat a wider range of bacterial infections compared to using amoxicillin alone.

Q: What are the most common side effects listed for Clavet?

A: Based on clinical trial data found in the official product information, the most frequently reported adverse reactions include temporary issues such as diarrhea or loose stools, nausea, vomiting, and skin rashes. Information regarding possible adverse reactions is included in the official documentation.

Q: Are there any specific foods or drinks to avoid while taking Clavet?

A: The official instructions advise taking the oral forms of the medicine at the start of a meal. This practice is recommended to help improve how the body absorbs the drug and to minimize the chance of gastrointestinal upset, like stomach aches. The official label generally does not list restrictions on specific foods.

Q: Does Clavet interact with alcohol?

A: Core regulatory documents generally do not list a direct chemical interaction between the active components of Clavet and alcohol. However, healthcare professional guidance may recommend caution because consuming alcohol can potentially worsen common gastrointestinal side effects such as nausea and diarrhea.

Q: Does Clavet interact with common pain relievers like ibuprofen?

A: The official drug interaction section in the regulatory label focuses primarily on specific prescription drugs like Probenecid and Methotrexate. Common over-the-counter non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen are generally not listed as a key interaction in the core product information.

Q: What happens if I forget to take a dose of Clavet?

A: Patient information derived from regulatory texts typically advises that if a dose is missed, it can be taken as soon as it is remembered. However, if it is close to the time for the next scheduled dose, the information states the missed dose should be skipped to maintain the regular schedule.

Q: Is Clavet safe to use during pregnancy?

A: The FDA classified this medicine as Pregnancy Category B. This means studies in animals have not shown a risk to the fetus, but there are limited controlled studies in humans. Official guidance indicates that the medicine should only be used during pregnancy when there is a clear medical need.

Q: Are the side effects of Clavet permanent?

A: The regulatory label indicates that certain rare but severe effects, such as liver toxicity, are generally considered reversible. While side effects are typically temporary, any severe, persistent, or concerning symptom is a reason to seek medical evaluation.

Q: What is the longest period of time people have studied taking Clavet?

A: Official prescribing guidance specifies that a single course of Clavet treatment should generally not be extended beyond 14 days without being re-evaluated by a clinician. This duration is specified in regulatory documentation based on safety considerations.

Q: Does Clavet need to be stored in the refrigerator?

A: Storage instructions vary depending on the specific form of the medicine. Tablets are typically stored at cool room temperature and protected from moisture. However, the liquid suspension requires refrigeration after it is mixed from the powder and must be discarded after a set time, typically ten days.

Q: Can Clavet interact with herbal supplements?

A: While the regulatory label lists interactions with specific prescription drugs, it is standard practice to disclose all co-administered agents, including herbal supplements, to a healthcare professional, as only prescription interactions may be explicitly listed in the label. This helps manage the potential for unforeseen effects.

Q: What types of allergic reactions are associated with Clavet?

A: Official warnings note that serious and potentially fatal allergic reactions, including anaphylaxis, have been reported with this drug class. Other severe skin reactions include Stevens–Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). The occurrence of a severe rash or difficulty breathing is a sign to seek medical evaluation.

Q: What are the ingredients in Clavet besides the active one?

A: The active components are amoxicillin and clavulanic acid. The inactive ingredients, or excipients, vary by product form. For example, regulatory information specifically warns that chewable tablets and oral suspensions may contain phenylalanine (aspartame).

Q: How quickly does Clavet leave the body?

A: Pharmacokinetics (how the body handles the drug) are described in the official label. The elimination half-life, which measures how long it takes for half the drug to be removed, is approximately 1.3 hours for amoxicillin and approximately 1.0 hour for clavulanic acid.

Q: Why do I need a prescription for Clavet?

A: As an antibacterial agent, Clavet requires a prescription from a licensed practitioner. Regulatory bodies mandate this status to ensure the medicine is only used when a bacterial infection is confirmed or strongly suspected. This careful approach is essential for limiting the public health risk of developing drug-resistant bacteria.

Q: Is Clavet commonly prescribed in other countries?

A: The combination of amoxicillin and clavulanic acid is the subject of official regulatory guidance and prescribing information from major international authorities, including the EMA (European Medicines Agency). This indicates its widespread acceptance and use across many global health systems.

Q: Is it possible to become dependent on Clavet?

A: Official regulatory documents do not contain warnings or sections related to abuse or physical dependence for this medicine. As an antibacterial drug, it is not associated with the same risks of dependence found with controlled substances.

Q: Does Clavet contain any common allergens like gluten or lactose?

A: The full product description lists all ingredients. Regulatory documents specifically note the presence of phenylalanine in some forms (chewable tablets and suspension). The full ingredient list of the specific formulation should be reviewed for patients with known sensitivities, such as to gluten or lactose.

Q: Can Clavet be crushed or split?

A: Instructions for physical alteration depend entirely on the formulation. While some tablets may be scored and can be split, others (like extended-release tablets) must be swallowed whole. The official administration instructions for the specific product must be followed to confirm if crushing or splitting is permitted.

Q: What if I take too much Clavet by mistake?

A: Overdosage can cause symptoms such as diarrhea, stomach pain, or sleepiness. Official product information advises that in case of a suspected overdose or severe symptoms, immediate emergency medical assistance should be sought.

Q: Is the effectiveness of Clavet affected by patient age?

A: While effectiveness is generally expected, official guidance mandates different dosing strategies based on age (pediatric, older adults) and weight, especially for children. These adjustments are necessary to ensure the patient receives the appropriate therapeutic exposure of the medicine.

Q: What does the research say about the long-term use of Clavet?

A: Based on official guidance, the treatment course is generally limited to 14 days or less. Use beyond this period requires mandatory clinical re-evaluation due to potential safety concerns, particularly the risk of liver dysfunction associated with prolonged use.

Q: Are there any specific monitoring tests required while taking Clavet?

A: The regulatory label advises that blood tests to monitor liver function should be considered, especially for patients who have existing liver impairment. For patients taking blood-thinning medicine (anticoagulants), monitoring of their Prothrombin Time (INR) is also often advised.

How should Clavet be stored and disposed of?

How to Store and Dispose of Clavet?

The official storage requirements for Clavet (Amoxicillin/Clavulanic Acid) vary significantly based on the product form to ensure stability and potency, as directed by regulatory labeling.

  • Tablets (Dry Product): Must be kept in a tightly closed container at room temperature (e.g., 20 C to 25 C) and protected from excess heat and moisture.
  • Oral Suspension (Liquid): The reconstituted liquid must be refrigerated at 2 C to 8 C (36 F to 46 F). The liquid must not be frozen.

Stability and Disposal

The liquid suspension has a limited stability period once mixed. It must be discarded after 10 days, even if it has been continuously refrigerated. All unused or expired medicine must be disposed of according to official local guidelines for pharmaceutical waste, and must not be poured into wastewater or sewers. For safety, the medication must always be stored out of the sight and reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Clavet found in:

A-Z Index: